Molten Ventures led the Series B round to support the creation of an artificial intelligence imaging lab.
"There was an area to go and help these pharma companies do better clinical trials, and so that’s how the company started"
XTX Ventures is the venture capital arm of XTX Markets, investing in early-stage companies where AI and machine learning are a core technology.
Portfolio
14
companies
BlueSkeye AI
BlueSkeye AI builds face and voice analysis technology to assess mood and mental wellbeing.

Cognitive Credit
Cognitive Credit builds data and analytics software for corporate credit markets.
Graide
Graide offers an AI-powered assessment platform that helps educators mark student assignments.
InvenireX
InvenireX builds a DNA nanotechnology platform to detect disease at early biological stages.
Logically
Logically uses advanced artificial intelligence to tackle online mis- and disinformation at scale.

Lucida Medical
Lucida Medical develops artificial intelligence software to accelerate and improve cancer diagnostics from MRI scans.
Oriole Networks
Oriole Networks builds photonic networking technology to connect AI accelerators using light instead of electricity.
QMatter
QMatter develops software that compresses quantum algorithms for pharmaceutical research.
Qureight
Artificial intelligence imaging platform for lung and heart clinical trials.
REalyse
REalyse provides real estate data and analytics for property professionals.
SOLVE Chemistry
SOLVE Chemistry develops artificial intelligence and hardware to modernise chemical research and manufacturing.
TILKI
TILKI develops an artificial intelligence platform that enables anyone to build video games without code.

Turbine
Turbine builds cell simulation software to predict cancer treatment outcomes.
WealthKernel
WealthKernel builds digital investment infrastructure via an API to help businesses launch wealth management services.
Ekaterina Holt
Head of XTX Ventures
Oliver Scott
Global Head of Treasury at XTX Markets
Gabriele Papievyte
Head of Ventures
Gabriele heads ventures at XTX Markets and advises the Department for Science, Innovation and Technology. She also holds investor and board roles across several technology companies.
LinkedInMolten Ventures led the Series B round to support the creation of an artificial intelligence imaging lab.
"There was an area to go and help these pharma companies do better clinical trials, and so that’s how the company started"
The funding supports the development of optical networking technology designed to remove electronic switches from data centre cores.
"A year ago, we were proving the physics; today, we’re proving the business. Our collaboration with AMD has moved from concept to deployment to a system an order of magnitude larger, and the data proves this is already driving performance increases at pace,"
The pre_seed round was led by 55 North to support platform expansion and upcoming pharmaceutical pilots.
"Early on in our research, we started looking at ways to get the most out of the quantum devices we had access to. That’s where some of these ideas started to form, which have eventually become what we’re now calling quantum compression,"
The funding round included participation from XTX Ventures and Macmillan Cancer Support to accelerate deployment and expand diagnostics.
"Cancer imaging volumes are rising rapidly but reporting capacity is not keeping pace. Our goal is to give clinicians faster, more confident decisions while reducing unnecessary interventions for patients. With our deep focus on prostate cancer and strong clinical validation across NHS pathways, we’re showing how AI can deliver earlier and more accurate diagnoses. In the NHS, few Trusts can confirm or rule out cancer within 28 days, and some patients can wait two months or longer. Lucida Medical is ideally placed to reduce this burden, and this funding will allow us to do that faster."
The seed round was led by XTX Ventures to expand team capacity and boost production capabilities.
"Across the different chemical industries everyone wants to be more efficient and produce the compounds society needs quicker, despite the challenges industry faces. We are helping pharmaceutical, agrochemical, and specialty chemical companies do just that."